N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy

Journal of Hypertension

Volumn 24, Issue 8, 2006, Pages 1531-1539

  Olsen, Michael H ^a,c   Wachtell, Kristian ^a,b,c   Nielsen, Olav W ^c   Hall, Christian ^c   Wergeland, Ragnhild ^c   Ibsen, Hans ^a   Kjeldsen, Sverre E ^d   Devereux, Richard B ^b   Dahlöf, Björn ^e   Hildebrandt, Per R ^a,f  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Albuminuria; Cardiovascular risk factors; High sensitivity C reactive protein; Hypertension; Left ventricular hypertrophy; N terminal pro brain natriuretic peptide; Natriuretic peptides; Prognosis; Urine albumin:creatinine ratio

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STROKE; TURBIDIMETRY;

EID: 33746698984     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000239288.10013.04     Document Type: Article

References (29)

1. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH,Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
2. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760-1763.
3. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593.
4. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147:931-938.
5. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609-1616.
6. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86:21-26.
7. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
8. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
9. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92:29-34.
10. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18:1121-1128.
11. Yamamoto K, Burnett JCJ, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994.
12. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens 1999; 21:583-593.
13. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22:1597-1604.
14. Hishiki S, Tochikubo O, Miyajima E, Ishii M. Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. J Hypertens 1998; 16:2101-2108.
15. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22:593-598.
16. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46:660-666.
17. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-997.
18. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
19. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107-115.
20. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27:297-312.
21. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306:1722-1725.
22. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561-577.
23. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25:669-676.
24. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
25. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002; 144:449-455.
26. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997; 77:264-267.
27. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol 2005; 20:407-416.
28. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 1995; 88:629-633.
29. Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P. N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Cardiac Fail 2005; 11 (5 Suppl.):70-75.